Non-alcoholic steatohepatitis (NASH) is a component of a wide spectrum of diseases that go from non-alcoholic fatty liver disease (NAFLD) to cirrhosis, and hepatocellular carcinoma in 40-60% of patients with NASH-related cirrhosis in a 5-7 year follow-up [1]. NASH has become one of the leading causes of liver disease in the developed world. With NAFLD believed to have doubled in the past 20 yea...

N on-alcoholic fatty liver disease (NAFLD) is a clinicopathological condition characterised by a wide spectrum of histological abnormalities and clinical outcomes. The underlying histological abnormality is hepatic steatosis, characterised by fat accumulation, which may progress to non-alcoholic steatohepatitis (NASH), characterised in turn by steatosis, periportal inflammation, and ballooning ...

Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic liver diseases in developed western countries. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD, and can progress to more severe forms of liver disease, including fibrosis, cirrhosis, and even hepatocellular carcinoma. The activation of hepatic stellate cells plays a critical role in NAS...

ALTHOUGH its histological features had long been recognized (1). the term non-alcoholic steatohepatitis (NASH) was first used by Ludwig et al. as recently as 1980 (2). Although it is commonly encountered in hepatology outpatient (office) practice (3). surprisingly little attention has been paid to NASH. It will be the purpose of this review to examine the clinical and pathological features of N...

Edgard Delvin CHU Sainte-Justine Research Center, 3175 Côte Ste-Catherine, Montreal, Quebec, Canada, H3T 1C5 e-mail: delvineasympatico.ca. Tel: (450) 681-1715 Summary: The rapidly increasing prevalence of childhood obesity and its associated co-morbidities such as hypertriglyceridemia, hyper-insulinemia, hypertension, early atherosclerosis, metabolic syndrome, and non-alcoholic fatty liver dise...

Non-alcoholic steatohepatitis has emerged as a major public health problem, and the burden of non-alcoholic cirrhosis is projected to increase by 64%-156% 2030. The threat aggravated fact that are currently no approved drugs for treatment steatohepatitis. In this paper, we review main challenges drug development in patients with cirrhosis, describe opportunities brought advances understanding c...

Non-alcoholic fatty liver disease (NAFLD) may be present as simple steatosis and progress to non-alcoholic steatohepatitis (NASH). This inflammation of the liver tissue is a prerequisite to hepatic fibrosis and cirrhosis. NAFLD represents an important and common cause of liver disease worldwide. It is commonly associated with other medical problems such as obesity, cardiovascular disease, diabe...